ASCK
ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY
24/09/2025
Voltar para busca
Dado oficial do USPTO
PRECIGEN
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: VerbalEscritório: US
Snapshot rápido
PRECIGEN
ST13
US500000087366798Classe
1, 5, 42, 44, 45
Pedido
87366798
Registro
7026015
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
62
Atualização mais recente
25/09/2025
Classificação
Registrada
Tipo de marca
Verbal
Classes Nice
1, 5, 42, 44, 45
Data de depósito
10/03/2017
Data de registro
11/04/2023
Data de expiração
-
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
11/04/2023
Última transação
25/09/2025
Escritório responsável
United States Patent and Trademark Office
Código da situação
700
Cadastro oficial
Principal Register
Fundamento do pedido
Intent to use
Primeiro uso
2019-04-00
Primeiro uso no comércio
2019-04-00
Código do desenho
4
Tipo de titular
03
Localização do titular
Blacksburg, VA
Examinador
HUDSON, TAMARA
Unidade examinadora
L40
Localização atual
PUBLICATION AND ISSUE SECTION
Titulares e representantes
Titulares
PRECIGEN, INC.
PRECIGEN, INC.
I. C. (pessoa física)
Representantes
David R. Kelly Barnes & Thornburg LLP
Classificação técnica
Classes Nice
Classe 1Classe 5Classe 42Classe 44Classe 45
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 1
Chemicalsbiochemicals and reagents for use in industry and science; chemicalsbiochemicals and reagentsproteins for regulatingmodifying or restricting gene expression; kits consisting primarily of proteins for regulatingmodifying or restricting gene expression
Classe 5
Chemical preparations for medical and veterinary purposesfor gene and cell therapy for treating genetic disorderscancersrare diseasesinfectious diseasescardiovascular and immunological diseases and disorders; biochemical preparations for medical and veterinary purposesfor gene and cell therapy for treating genetic disorderscancersrare diseasesinfectious diseasescardiovascular and immunological diseases and disorders; chemical reagents for medical and veterinary purposesfor gene and cell therapy for treating genetic disorderscancersrare diseasesinfectious diseasescardiovascular and immunological diseases and disorders
Classe 42
Scientific research and development services in the field of medicinepharmacologyimmunologybiochemistrycell biologygeneticsmicrobiology and virology; Scientific research in the field of healthcare; Therapeutic research of treatments in the fields of oncologyrare diseasesmetabolic disordersinfectious diseasesophthalmologycardiovascular disease which are under development or have completed development; Development of products being genetic therapiesbiopharmaceuticalseffectors to regulatemodulatecharacterize disease states; Development of tools in the nature of software and biotechnological processes to regulatemodulatecharacterize disease states; Research and development services for others in the field of biotechnologygenetically engineering DNAbiological organismscellsvirusespathogensspecial purpose cells for scientificresearchmedical and laboratory use; Research and development services for others in the fields of genetics and biotechnologygenetically engineering DNAbiological organismscellsvirusespathogensspecial purpose cells for scientificresearchmedical and laboratory use
Classe 44
Medical services; Medical servicesgenetic engineeringbiopharmaceuticals and gene therapy services; Healthcare servicestreatment of patients with genetic disorderscancersrare diseasesinfectious diseasescardiovascular and immunological diseases and disorders; Medical servicesproviding medical therapy treatments which are under development or have completed development for patients in the fields of oncologyrare diseasesmetabolic disordersinfectious diseasesophthalmologycardiovascular diseases
Classe 45
Technology transfer serviceslicensing of intellectual property
Publicações
Histórico de despachos e eventos da marca no USPTO.
62 publicações encontradas
ASCK
ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY
07/02/2024
NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
11/04/2023
R.PR
REGISTERED-PRINCIPAL REGISTER
11/04/2023
SUNA
NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
07/03/2023
CNPR
ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
06/03/2023
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
23/02/2023
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
23/02/2023
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
23/02/2023
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
13/12/2022
GNRT
NON-FINAL ACTION E-MAILED
13/12/2022
CNRT
SU - NON-FINAL ACTION - WRITTEN
13/12/2022
SUPC
STATEMENT OF USE PROCESSING COMPLETE
19/10/2022
IUAF
USE AMENDMENT FILED
17/10/2022
EISU
TEAS STATEMENT OF USE RECEIVED
17/10/2022
CHAN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
31/05/2022
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
31/05/2022
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
31/05/2022
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
31/05/2022
COAR
TEAS CHANGE OF OWNER ADDRESS RECEIVED
31/05/2022
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
12/04/2022
EX5G
SOU EXTENSION 5 GRANTED
11/04/2022
EXT5
SOU EXTENSION 5 FILED
08/04/2022
EEXT
SOU TEAS EXTENSION RECEIVED
08/04/2022
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
22/10/2021
EX4G
SOU EXTENSION 4 GRANTED
20/10/2021
EXT4
SOU EXTENSION 4 FILED
20/10/2021
EEXT
SOU TEAS EXTENSION RECEIVED
20/10/2021
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
22/04/2021
EX3G
SOU EXTENSION 3 GRANTED
20/04/2021
EXT3
SOU EXTENSION 3 FILED
20/04/2021
EEXT
SOU TEAS EXTENSION RECEIVED
20/04/2021
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
24/10/2020
EX2G
SOU EXTENSION 2 GRANTED
22/10/2020
EXT2
SOU EXTENSION 2 FILED
22/10/2020
EEXT
SOU TEAS EXTENSION RECEIVED
22/10/2020
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
11/04/2020
EX1G
SOU EXTENSION 1 GRANTED
10/04/2020
AITU
CASE ASSIGNED TO INTENT TO USE PARALEGAL
10/04/2020
EXT1
SOU EXTENSION 1 FILED
08/04/2020
EEXT
SOU TEAS EXTENSION RECEIVED
08/04/2020
ASGN
AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP
08/04/2020
NOAM
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
22/10/2019
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
27/08/2019
PUBO
PUBLISHED FOR OPPOSITION
27/08/2019
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
07/08/2019
ALIE
ASSIGNED TO LIE
19/07/2019
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
10/07/2019
RCSC
REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED
21/12/2018
RCSC
REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED
21/06/2018
GNS3
NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
21/12/2017
GNSL
LETTER OF SUSPENSION E-MAILED
21/12/2017
CNSL
SUSPENSION LETTER WRITTEN
21/12/2017
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
06/12/2017
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
05/12/2017
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
05/12/2017
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
05/06/2017
GNRT
NON-FINAL ACTION E-MAILED
05/06/2017
CNRT
NON-FINAL ACTION WRITTEN
05/06/2017
DOCK
ASSIGNED TO EXAMINER
05/06/2017
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
16/03/2017
NWAP
NEW APPLICATION ENTERED
14/03/2017
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace PRECIGEN ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.